prolong
viral
shed
associ
sever
statu
poor
prognosi
patient
unexpectedli
report
nonsever
patient
longest
durat
viral
shed
accord
investig
clinic
epidemiolog
inform
case
conclud
type
viru
might
low
toxic
transmiss
prolong
infect
abil
hardli
elimin
bodi
regular
therapi
howev
infus
plasma
recov
patient
show
high
effici
elimin
viru
find
might
shed
light
manag
coronaviru
caus
sever
acut
respiratori
syndrom
coronaviru
becom
threat
global
health
clinic
spectrum
patient
present
divers
viral
shed
critic
indic
prognosi
prolong
viral
shed
alway
predict
poor
outcom
report
howev
describ
special
case
famili
cluster
mild
type
one
famili
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
member
durat
ill
onset
persist
day
till
longest
durat
viral
shed
symptomat
patient
far
know
nevertheless
case
show
mild
infect
better
statu
compar
case
fortun
treatment
plasma
recov
patient
effici
clear
viru
infect
report
describ
detail
epidemiolog
clinic
inform
special
patient
close
contact
might
provid
rational
reason
treatment
riskstratif
strategi
commun
healthcar
manag
policymak
hierarch
medic
case
diagnos
classifi
accord
new
coronaviru
pneumonia
diagnosi
program
edit
commiss
china
clinic
manifest
consist
four
categori
mild
moder
sever
critic
mild
clinic
symptom
mild
pulmonari
inflamm
imag
without
symptom
respiratori
infect
moder
overwhelm
major
show
symptom
respiratori
infect
fever
cough
sputum
pulmonari
inflamm
imag
symptom
dyspnea
appear
includ
follow
short
breath
rr
blood
oxygen
satur
rest
pao
fio
mmhg
pulmonari
inflamm
progress
significantli
within
hour
classifi
sever
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
respiratori
failur
shock
organ
failur
requir
intens
care
critic
ill
studi
case
taken
one
design
hospit
local
author
wuhan
citi
hubei
provinc
china
studi
approv
ethic
committe
hospit
subject
sign
inform
consent
form
admiss
hospit
patient
includ
discharg
dead
hospit
januari
march
investig
clinic
index
use
refer
hospit
patient
case
would
introduc
detail
studi
case
moder
type
case
sever
type
case
critic
ill
type
die
anoth
patient
case
close
rel
case
also
follow
patient
confirm
viral
detect
use
quantit
rtpcr
rule
infect
respiratori
virus
influenza
viru
influenza
viru
b
coxsacki
viru
respiratori
syncyti
viru
parainfluenza
viru
enteroviru
time
studi
basic
inform
clinic
symptom
complet
blood
count
coagul
profil
serum
biochem
test
includ
renal
liver
function
creatin
kinas
lactat
dehydrogenas
electrolyt
diseas
outcom
includ
patient
collect
epidemiolog
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
data
investig
patient
case
also
collect
studi
graphpad
softwar
use
data
statist
map
data
display
descript
middleag
man
visit
hospit
requir
test
tabl
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
fig
noteworthili
level
blood
lymphocyt
procalcitonin
recogn
indic
diseas
sever
prognosi
patient
us
other
three
index
normal
stabl
patient
fig
viral
load
persist
high
level
sever
critic
ill
patient
fig
notabl
igg
antibodi
show
posit
feb
mar
igm
antibodi
test
remain
neg
given
prolong
infect
patient
receiv
plasma
infus
treatment
plasma
collect
recov
patient
mar
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
case
receiv
ml
plasma
patient
got
fever
hour
infus
bodi
temperatur
consid
blood
transfus
reaction
expect
bodi
temperatur
becam
normal
next
day
notabl
viral
test
via
oropharyng
swab
mar
mar
turn
neg
epidemiolog
survey
reveal
besid
rel
patient
close
contact
anoth
five
peopl
admiss
one
contact
also
got
fever
short
term
test
show
neg
four
contact
without
symptom
also
neg
test
case
close
rel
case
elderli
woman
visit
hospit
patient
prescrib
antivir
medicin
chines
tradit
medicin
howev
fever
absolut
control
receiv
treatment
day
notabl
patient
histori
rheumatoid
arthriti
ra
long
term
use
methylprednisolon
mg
oral
qd
tabl
fig
admiss
physic
examin
show
bodi
temperatur
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
tabl
fig
report
median
durat
viral
shed
day
diseas
onset
longest
day
signific
differ
sever
patient
day
critic
patient
day
report
durat
viral
shed
ill
onset
case
persist
day
longest
ever
report
symptomat
patient
previou
studi
indic
level
durat
viral
shed
critic
indic
access
risk
transmiss
guid
isol
patient
well
predict
prognosi
viral
infect
prolong
viral
shed
associ
inferior
outcom
interestingli
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
given
case
histori
longterm
use
glucocorticoid
highrisk
factor
sever
infect
progress
overal
sever
case
much
optimist
averag
statu
age
group
sinc
report
elder
peopl
infect
much
wors
prognosi
furthermor
though
anoth
rel
also
got
fever
time
visit
viral
test
neg
indic
viru
may
promptli
clear
contact
infect
genet
mutat
may
consid
contribut
mild
sign
famili
cluster
case
one
import
thing
four
close
contact
blood
relationship
case
even
infect
contact
recent
one
studi
found
abo
blood
group
new
risk
factor
sever
patient
peopl
blood
group
higher
risk
patient
blood
group
lower
risk
group
howev
blood
group
case
group
ab
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
tabl
thu
exclud
possibl
blood
group
case
may
influenc
sever
ill
clue
togeth
indic
viru
case
case
may
mild
subtyp
young
old
peopl
tang
et
al
investig
molecular
diverg
show
viru
evolv
two
major
type
name
l
subtyp
subtyp
l
type
preval
consist
approxim
patient
type
ancestr
version
addit
l
type
high
frequenc
patient
present
like
spread
compar
type
current
studi
focus
identifi
clinic
featur
two
subtyp
thu
assur
case
viru
belong
type
mutat
l
type
new
subtyp
sinc
onset
time
case
reveal
mild
subtyp
alreadi
exist
earli
stage
outbreak
l
type
occupi
domin
posit
exclud
origin
new
subtyp
identifi
potenti
subtyp
show
quit
low
toxic
weak
transmiss
peopl
infect
type
show
affirm
outcom
worthi
us
analyz
mrna
sequenc
viru
type
isol
case
help
us
distinguish
potenti
mild
patient
benefici
distribut
limit
medic
sourc
guid
commun
healthcar
manag
context
pandem
due
limit
capac
nucleic
acid
assay
identifi
reliabl
indic
distinguish
sever
patient
earli
stage
help
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
quickli
screen
patient
need
hospit
stay
home
statu
lymphocyt
durat
viral
shed
two
common
indic
predict
prognosi
patient
howev
still
unclear
one
reliabl
effici
present
studi
igg
antibodi
detect
case
feb
indic
case
initi
immun
respons
viral
infect
howev
mrna
level
viru
case
show
similar
trend
death
case
taken
togeth
find
indic
immun
indic
could
sensit
reliabl
viral
shed
reflect
overal
statu
patient
predict
prognosi
actual
recent
studi
found
recruit
cell
presenc
igg
igm
antibodi
found
resolut
symptom
patient
therefor
strongli
suggest
immun
indic
especi
level
lymphocyt
could
better
prognost
indic
durat
viral
shed
especi
patient
earli
stage
next
would
like
find
sign
may
also
potenti
prognost
factor
besid
level
lymphocyt
earli
stage
ill
report
median
durat
fever
patient
day
obvious
durat
fever
two
case
shorter
averag
durat
indic
case
case
get
fever
initi
onset
control
quickli
well
known
fever
inhibit
viral
replic
save
respons
time
immun
cell
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
howev
fever
persist
fever
often
indic
defici
immun
system
worsen
prognosi
also
appli
patient
find
indic
immun
system
two
case
work
well
stimul
infect
viru
thu
specul
rapidli
control
fever
could
one
reason
candid
predict
sever
patient
earli
stage
togeth
combin
statu
fever
level
lymphocyt
may
becom
effici
indic
earli
predic
prognosi
patient
plasma
infus
treatment
new
therapeut
method
patient
effici
still
need
investig
case
prolong
infect
case
rapidli
elimin
infus
impli
method
might
potent
treatment
patient
howev
longterm
outcom
complic
investig
although
evid
collect
two
case
indic
better
prognosi
patient
long
durat
viral
shed
mild
type
like
neglect
crowd
may
persist
infect
surround
caus
new
outbreak
viral
test
case
chang
neg
ill
day
howev
revers
posit
ill
day
fig
like
viru
host
got
dynam
balanc
viral
load
indic
immun
cell
maintain
stabl
fig
although
viral
duplic
suppress
immun
cell
clear
viru
case
may
tend
chronic
infect
case
without
infus
treatment
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
viru
host
may
even
form
symbiot
relationship
wonder
mani
patient
involv
situat
one
import
question
whether
long
kind
patient
keep
infect
import
question
whether
chronic
infect
patient
infect
new
rout
transmiss
sexual
transmiss
moreov
due
high
mutat
rate
retroviru
keep
close
eye
statu
kind
patient
infect
abil
report
clinic
featur
special
famili
cluster
case
one
member
longest
durat
viral
shed
current
report
besid
long
durat
sever
point
also
concern
firstli
viru
infect
famili
cluster
case
appear
low
toxic
low
transmiss
howev
also
show
prolong
infect
abil
hardli
elimin
bodi
viru
type
may
exist
human
bodi
long
time
may
risk
contribut
period
outbreak
futur
consid
high
mutat
secondli
rapidli
control
fever
normal
level
immun
cell
may
good
predictor
identifi
patient
superior
outcom
earli
stage
conclus
need
valid
care
design
clinic
studi
thirdli
plasma
infus
could
effici
therapi
patient
last
long
term
health
statu
infect
abil
peopl
need
follow
due
prolong
infect
report
provid
valuabl
inform
public
health
manag
decis
make
triag
longterm
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
moderatecur
moder
type
case
cure
outcom
pct
procalcitonin
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
